Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of BMS-986231 (Cimlanod) in Subjects With Varying Renal Function
NCT03332186Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of cimlanod in heart failure (HF) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration at 11 days, Area under the concentration-time curve from time 0 extrapolated to infinity at 11 days and 3 more. Started Mar 2018; status: completed.
02
Drugs
cimlanod
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT03332186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03332186.